Literature DB >> 26510688

Slow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response.

L Samaranch1, P Hadaczek1, A P Kells1, J R Bringas1, D Stockinger2, W San Sebastian1, M Macayan1, S Samineni2, P Pivirotto1, J Forsayeth1, K S Bankiewicz1.   

Abstract

Adeno-associated virus serotype 2 (AAV2) has previously been reported to be a slowly uncoating virus in peripheral tissues, but persistence of intact vector in primate brain has not been explored. Because some neurological gene therapies may require re-administration of the same vector to patients, it seems important to understand the optimal timeframe in which to consider such repeat intervention. Surprisingly, convection-enhanced delivery of AAV2 into the thalamus of nonhuman primates (NHPs) resulted in robust staining of neurons with A20 antibody that detected intact AAV2 particles at ∼1.5 months after infusion. However, by 2.5 months, no A20 staining was visible. These data confirmed earlier findings of persistence of intact AAV2 particles in ocular and hepatic tissues. In order to probe the potential consequences of this persistence, we infused AAV2-human aromatic L-amino acid decarboxylase into left and right thalamus of three NHPs, with a 3-month delay between infusions. During that interval, we immunized each animal subcutaneously with AAV2 virus-like particles (empty vector) in order to induce strong anti-capsid humoral immunity. Various high neutralizing antibody titers were achieved. The lowest titer animal showed infiltration of B lymphocytes and CD8(+) T cells into both the secondary and primary infusion sites. In the other two animals, extremely high titers resulted in no transduction of the second site and, therefore, no lymphocytic infiltration. However, such infiltration was prominent at the primary infusion site in each animal and was associated with overt neuronal loss and inflammation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26510688     DOI: 10.1038/gt.2015.87

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  25 in total

1.  Input virion proteins: cryptic targets of antivector immune responses in preimmunized subjects.

Authors:  Pedro R Lowenstein
Journal:  Mol Ther       Date:  2004-06       Impact factor: 11.454

2.  Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors.

Authors:  Clare E Thomas; Theresa A Storm; Zan Huang; Mark A Kay
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates.

Authors:  Knut Stieger; Josef Schroeder; Nathalie Provost; Alexandra Mendes-Madeira; Brahim Belbellaa; Guylène Le Meur; Michel Weber; Jack-Yves Deschamps; Birgit Lorenz; Philippe Moullier; Fabienne Rolling
Journal:  Mol Ther       Date:  2008-12-23       Impact factor: 11.454

4.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Guangping Gao; Jianping Lin; James M Wilson
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

5.  Convection-enhanced delivery of macromolecules in the brain.

Authors:  R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

6.  Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors.

Authors:  Xiaomin Su; Adrian P Kells; Ernesto A Salegio; Ernesto Aguilar Salegio; R Mark Richardson; Piotr Hadaczek; Janine Beyer; John Bringas; Philip Pivirotto; John Forsayeth; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

7.  Adeno-associated virus antibody profiles in newborns, children, and adolescents.

Authors:  Roberto Calcedo; Hiroki Morizono; Lili Wang; Robert McCarter; Jianping He; David Jones; Mark L Batshaw; James M Wilson
Journal:  Clin Vaccine Immunol       Date:  2011-07-20

8.  Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.

Authors:  Anne-Kathrin Zaiss; Qiang Liu; Gloria P Bowen; Norman C W Wong; Jeffrey S Bartlett; Daniel A Muruve
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.

Authors:  Agnieszka Ciesielska; Piotr Hadaczek; Gabriele Mittermeyer; Shangzhen Zhou; J Fraser Wright; Krystof S Bankiewicz; John Forsayeth
Journal:  Mol Ther       Date:  2012-08-28       Impact factor: 11.454

10.  A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer.

Authors:  Hua Li; Shih-Wen Lin; Wynetta Giles-Davis; Yan Li; Dongming Zhou; Zhi Quan Xiang; Katherine A High; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

View more
  3 in total

1.  AAV-mediated delivery of optogenetic constructs to the macaque brain triggers humoral immune responses.

Authors:  Skyler D Mendoza; Yasmine El-Shamayleh; Gregory D Horwitz
Journal:  J Neurophysiol       Date:  2017-02-15       Impact factor: 2.714

2.  Glymphatic fluid transport controls paravascular clearance of AAV vectors from the brain.

Authors:  Giridhar Murlidharan; Andrew Crowther; Rebecca A Reardon; Juan Song; Aravind Asokan
Journal:  JCI Insight       Date:  2016-09-08

3.  MRI-guided intracerebral convection-enhanced injection of gliotoxins to induce focal demyelination in swine.

Authors:  Lukasz Kalkowski; Izabela Malysz-Cymborska; Dominika Golubczyk; Miroslaw Janowski; Piotr Holak; Kamila Milewska; Dorota Kedziorek; Zbigniew Adamiak; Wojciech Maksymowicz; Piotr Walczak
Journal:  PLoS One       Date:  2018-10-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.